Abstract
The TRPV1 vanilloid receptor, first cloned and characterized in 1997, is a non selective cation channel expressed in primary sensory neurons, and is a key pain sensor and integrator. Activators of this receptor are varied and include capsaicin, the pungent phenolic principle from hot chilli peppers, endogenous lipid anandamide, noxious heat, and low extracellular pH. Agonists of the TRPV1 receptor have been investigated for development due to their analgesic effect that results from the receptor desensitization. However, all agonists including capsaicin cause initial burning effect, and have the potential for other undesirable effects, which complicates effective therapy. The development of animal pain models involving TRPV1 receptor blockade through small molecules and characterization of TRPV1 knockout mice models in recent years has provided a compelling argument in favor of pursuing the development of selective TRPV1 antagonists as novel analgesic agents. This article will provide an overview of the various chemical classes of agonists and antagonists of TRPV1 receptor along with their therapeutic potential and possible side effects.
Keywords: TRPV1 receptor antagonists, vanilloids, structure activity relationships, agonist binding site, pain modulation
Current Bioactive Compounds
Title: Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Volume: 4 Issue: 2
Author(s): Vijaya L. Korlipara
Affiliation:
Keywords: TRPV1 receptor antagonists, vanilloids, structure activity relationships, agonist binding site, pain modulation
Abstract: The TRPV1 vanilloid receptor, first cloned and characterized in 1997, is a non selective cation channel expressed in primary sensory neurons, and is a key pain sensor and integrator. Activators of this receptor are varied and include capsaicin, the pungent phenolic principle from hot chilli peppers, endogenous lipid anandamide, noxious heat, and low extracellular pH. Agonists of the TRPV1 receptor have been investigated for development due to their analgesic effect that results from the receptor desensitization. However, all agonists including capsaicin cause initial burning effect, and have the potential for other undesirable effects, which complicates effective therapy. The development of animal pain models involving TRPV1 receptor blockade through small molecules and characterization of TRPV1 knockout mice models in recent years has provided a compelling argument in favor of pursuing the development of selective TRPV1 antagonists as novel analgesic agents. This article will provide an overview of the various chemical classes of agonists and antagonists of TRPV1 receptor along with their therapeutic potential and possible side effects.
Export Options
About this article
Cite this article as:
Korlipara L. Vijaya, Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294235
DOI https://dx.doi.org/10.2174/157340708785294235 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Toll-like Receptors and Diabetes Complications: Recent Advances
Current Diabetes Reviews Exploring Newer Target Sodium Glucose Transporter 2 for the Treatment of Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design Genomics, Proteomics and Metabolomics Approaches for Predicting Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews Diabetic Papillopathy: Current and New Treatment Options
Current Diabetes Reviews Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Role of NFAT5 in Inflammatory Disorders Associated with Osmotic Stress
Current Genomics Neural Control of Blood Pressure: Focusing on Capsaicin-Sensitive Sensory Nerves
Cardiovascular & Hematological Disorders-Drug Targets Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Some Recent Approaches of Biologically Active Substituted Pyridazine and Phthalazine Drugs
Current Medicinal Chemistry Vaccines and Photodynamic Therapies for Oral Microbial-Related Diseases
Current Drug Metabolism Long-term Potentiation at Spinal C-fiber Synapses: A Target for Pathological Pain
Current Pharmaceutical Design A New Alzheimers Disease Interventive Strategy: GLP-1
Current Drug Targets Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design Novel Therapeutic Strategies Targeting Vascular Redox in Human Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery Diabetic Foot and Exercise Therapy: Step by Step The Role of Rigid Posture and Biomechanics Treatment
Current Diabetes Reviews Thiazolidine: A Potent Candidate for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design